Form 4: Teva Director Varda Shalev Reports RSU Vesting and New Grant, Alongside Significant Share Disposition

Teva Pharmaceutical Industries Ltd. Director Varda Shalev reported the vesting of 9,632 restricted share units and the grant of 14,492 new restricted share units, alongside the disposition of 22,504 ordinary shares.

Summary

• Varda Shalev, a Director of Teva Pharmaceutical Industries Ltd., reported transactions involving the company's securities.
• On June 6, 2025, 9,632 Restricted Share Units (RSUs) granted on June 6, 2024, vested, resulting in the acquisition of 9,632 ordinary shares.
• On the same date, 22,504 ordinary shares were disposed of by the reporting person. The price of this disposition was not disclosed in the filing.
• On June 5, 2025, Ms. Shalev was granted 14,492 new Restricted Share Units, which are scheduled to vest on June 5, 2026.
• Following these transactions, Ms. Shalev beneficially owns 14,492 Restricted Share Units.
• The transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there's a disposition of shares, which can sometimes be viewed negatively, it's offset by the vesting of existing RSUs and the grant of new RSUs, indicating continued director engagement and long-term incentive alignment. The transaction being under a 10b5-1 plan also reduces the negative implication of the sale.

Positives

• The grant of 14,492 new Restricted Share Units to Director Varda Shalev indicates continued alignment of management incentives with shareholder interests and a commitment to the company's future.
• The vesting of 9,632 Restricted Share Units represents a successful realization of prior compensation for the director.

Negatives

• The disposition of 22,504 ordinary shares by a director, without a disclosed price, could be interpreted as a sale, which might be seen as a negative signal by some investors, although it could also be for tax purposes or personal liquidity.

Future Outlook

The grant of 14,492 new Restricted Share Units to Director Varda Shalev, vesting on June 5, 2026, indicates a continued long-term incentive for the director and aligns their future compensation with the company's performance.

Industry Context

This Form 4 filing details routine insider transactions related to director compensation and share management. It does not provide information that allows for analysis of broader industry trends or competitive positioning. Such filings are standard for publicly traded companies to ensure transparency regarding insider holdings.

Related Party Transactions

• The grant of 14,492 Restricted Share Units to Director Varda Shalev represents a compensation transaction between the company and a related party (director).

Stakeholder Impact

• Shareholders: The disposition of shares by a director could be viewed with slight concern, but the new RSU grant aligns the director's future interests with shareholder value. The Rule 10b5-1 plan indicates a pre-planned transaction rather than a reaction to new information.

Next Steps

• The 14,492 Restricted Share Units granted on June 5, 2025, are scheduled to vest on June 5, 2026.

Key Dates

Recommendation

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, SEC Filing, Insider Trading, Restricted Share Units, RSU, Director Compensation, Share Disposition, Varda Shalev, Rule 10b5-1